<?xml version='1.0' encoding='utf-8'?>
<document id="16443666"><sentence text="Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes."><entity charOffset="52-62" id="DDI-PubMed.16443666.s1.e0" text="bortezomib" /></sentence><sentence text="Bortezomib (Velcade, PS-341), a dipeptidyl boronic acid, is a first-in-class proteasome inhibitor approved in 2003 for the treatment of multiple myeloma"><entity charOffset="0-10" id="DDI-PubMed.16443666.s2.e0" text="Bortezomib" /><entity charOffset="12-19" id="DDI-PubMed.16443666.s2.e1" text="Velcade" /><entity charOffset="21-27" id="DDI-PubMed.16443666.s2.e2" text="PS-341" /><entity charOffset="43-55" id="DDI-PubMed.16443666.s2.e3" text="boronic acid" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e0" e2="DDI-PubMed.16443666.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e0" e2="DDI-PubMed.16443666.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e0" e2="DDI-PubMed.16443666.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e0" e2="DDI-PubMed.16443666.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e1" e2="DDI-PubMed.16443666.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e1" e2="DDI-PubMed.16443666.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e1" e2="DDI-PubMed.16443666.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e2" e2="DDI-PubMed.16443666.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16443666.s2.e2" e2="DDI-PubMed.16443666.s2.e3" /></sentence><sentence text=" In a preclinical toxicology study, bortezomib-treated rats resulted in liver enlargement (35%)"><entity charOffset="36-46" id="DDI-PubMed.16443666.s3.e0" text="bortezomib" /></sentence><sentence text=" Ex vivo analyses of the liver samples showed an 18% decrease in cytochrome P450 (P450) content, a 60% increase in palmitoyl coenzyme A beta-oxidation activity, and a 41 and 23% decrease in CYP3A protein expression and activity, respectively" /><sentence text=" Furthermore, liver samples of bortezomib-treated rats had little change in CYP2B and CYP4A protein levels and activities"><entity charOffset="31-41" id="DDI-PubMed.16443666.s5.e0" text="bortezomib" /></sentence><sentence text=" To address the likelihood of clinical drug-drug interactions, the P450 inhibition potential of bortezomib and its major deboronated metabolites M1 and M2 and their dealkylated metabolites M3 and M4 was evaluated in human liver microsomes for the major P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4/5"><entity charOffset="96-106" id="DDI-PubMed.16443666.s6.e0" text="bortezomib" /></sentence><sentence text=" Bortezomib, M1, and M2 were found to be mild inhibitors of CYP2C19 (IC(50) approximately 18"><entity charOffset="1-11" id="DDI-PubMed.16443666.s7.e0" text="Bortezomib" /></sentence><sentence text="0, 10" /><sentence text="0, and 13" /><sentence text="2 microM, respectively), and M1 was also a mild inhibitor of CYP2C9 (IC(50) approximately 11" /><sentence text="5 microM)" /><sentence text=" However, bortezomib, M1, M2, M3, and M4 did not inhibit other P450s (IC(50) values &gt; 30 microM)"><entity charOffset="10-20" id="DDI-PubMed.16443666.s12.e0" text="bortezomib" /></sentence><sentence text=" There also was no time-dependent inhibition of CYP3A4/5 by bortezomib or its major metabolites"><entity charOffset="60-70" id="DDI-PubMed.16443666.s13.e0" text="bortezomib" /></sentence><sentence text=" Based on these results, no major P450-mediated clinical drug-drug interactions are anticipated for bortezomib or its major metabolites"><entity charOffset="100-110" id="DDI-PubMed.16443666.s14.e0" text="bortezomib" /></sentence><sentence text=" To our knowledge, this is the first report on P450-mediated drug-drug interaction potential of proteasome inhibitors or boronic acid containing therapeutics"><entity charOffset="121-133" id="DDI-PubMed.16443666.s15.e0" text="boronic acid" /></sentence><sentence text="" /></document>